GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

251 papers

Active filtersClassification:Core

Showing 73-84 of total 251 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Real-World Impact of Weekly Dulaglutide and Semaglutide on Hba1c and Weight in a Predominantly Underrepresented Demographic.

Deas C; Uhomba L; Snow K

Jan 1, 2026

2026PubMedDirectly related

Adjuvant Glucagon-like Peptide-1 Receptor Agonist Therapy Post-Bariatric Surgery: An Exploratory Single-Institution Analysis.

Cross-Najafi AA; Benavidez MC; No JJ; Ngo KC; Redpath S; Nin DZ; Schimpke SW; Myers JA; Omotosho P; Torquati A; Skertich NJ

Jan 1, 2026The Journal of surgical research

2026PubMedDirectly related

Can Obesity Pharmacotherapy Modify Osteoarthritis? Interpreting Pain Relief, Weight-Loss Quality, and Structural Outcomes.

Rombach J; Hannani MT; Henriksen K; Bihlet AR; Bajaj M; He Y; Bay-Jensen AC; Thudium CS; Karsdal M

Jan 1, 2026Osteoarthritis and cartilage

2026PubMedDirectly related

Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice.

Bridges AG; Jackson T

Jan 1, 2026Clinics in dermatology

2026PubMedDirectly related

Combination pharmacotherapy for MASH: Potential synergistic approaches.

Meije DA; Holleboom AG; van de Graaf SFJ

Jan 1, 2026Biochemical pharmacology

2026PubMedDirectly related

Targeting the cardiohepatic-metabolic axis: GLP-1-based and incretin multi-agonist therapies in MASH.

Zhang YW; Hu Y

Jan 1, 2026British journal of clinical pharmacology

2026PubMedDirectly related

Association Between Continuous Glucose Monitoring Utilization and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Type 2 Diabetes: A Real-World Study.

Wright EE Jr; Huang E; Bindal A

Jan 1, 2026Diabetes technology & therapeutics

2026PubMedDirectly related

Aesthetic Considerations for Preventing and Managing GLP-1 Receptor Agonist-Related Facial Aging.

Bommareddy K; Fabi S; Muniz M

Jan 1, 2026The Journal of clinical and aesthetic dermatology

2026PubMedDirectly related

Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules.

Beibei Y; Yang D; Yifeng S; Wenjing T; Wanshan H; Wenhao W; Tingting P; Chuanbin W; Pan X

Jan 1, 2026International journal of pharmaceutics

2026PubMedDirectly related

Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan.

Tu ST; Chiu CF; Chou CK; Chuang HH; Hu SW; Ko WC; Lee CY; Lin WY; Sung YJ; Tzeng TF; Wang W; Wu HF; Yeung CY; Chen B; Sim CJ; Huang KC

Jan 1, 2026Endocrinology, diabetes & metabolism

2026PubMedDirectly related

A Novel Approach to Managing "Double Diabetes" in a Pediatric Patient on Insulin Pump Therapy: An Off-Label Use of a Fixed-Ratio Insulin Degludec/Liraglutide Combination.

Almoallem B; Thalange NK

Jan 1, 2026Cureus

2026PubMedDirectly related

Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue.

Li X; Liu Y; Wang F; Zhang F; Zhang L; Dang Y; Qi X

Jan 1, 2026Cardiovascular drugs and therapy